KR102299073B1 - 심부전에서 혈압을 조절하고 호흡곤란을 감소시키는 방법 - Google Patents

심부전에서 혈압을 조절하고 호흡곤란을 감소시키는 방법 Download PDF

Info

Publication number
KR102299073B1
KR102299073B1 KR1020157013890A KR20157013890A KR102299073B1 KR 102299073 B1 KR102299073 B1 KR 102299073B1 KR 1020157013890 A KR1020157013890 A KR 1020157013890A KR 20157013890 A KR20157013890 A KR 20157013890A KR 102299073 B1 KR102299073 B1 KR 102299073B1
Authority
KR
South Korea
Prior art keywords
blood pressure
clevidipine
patient
pharmaceutical composition
mmhg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157013890A
Other languages
English (en)
Korean (ko)
Other versions
KR20150104084A (ko
Inventor
에드워드 씨. 주니어. 스핀들러
로레타 엠. 이트리
그레고리 찰스 윌리암스
밍-이 후
Original Assignee
치에시 파마슈티시 에스.피.아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 치에시 파마슈티시 에스.피.아. filed Critical 치에시 파마슈티시 에스.피.아.
Publication of KR20150104084A publication Critical patent/KR20150104084A/ko
Application granted granted Critical
Publication of KR102299073B1 publication Critical patent/KR102299073B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157013890A 2012-10-26 2013-10-26 심부전에서 혈압을 조절하고 호흡곤란을 감소시키는 방법 Active KR102299073B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719127P 2012-10-26 2012-10-26
US61/719,127 2012-10-26
PCT/US2013/066990 WO2014066870A1 (en) 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure

Publications (2)

Publication Number Publication Date
KR20150104084A KR20150104084A (ko) 2015-09-14
KR102299073B1 true KR102299073B1 (ko) 2021-09-09

Family

ID=50545374

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157013890A Active KR102299073B1 (ko) 2012-10-26 2013-10-26 심부전에서 혈압을 조절하고 호흡곤란을 감소시키는 방법

Country Status (18)

Country Link
US (1) US10881645B2 (cg-RX-API-DMAC7.html)
EP (1) EP2925128B1 (cg-RX-API-DMAC7.html)
JP (2) JP6329957B2 (cg-RX-API-DMAC7.html)
KR (1) KR102299073B1 (cg-RX-API-DMAC7.html)
CN (2) CN110840890A (cg-RX-API-DMAC7.html)
AU (1) AU2013334081B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015009291B1 (cg-RX-API-DMAC7.html)
CA (1) CA2889584C (cg-RX-API-DMAC7.html)
EA (1) EA030354B1 (cg-RX-API-DMAC7.html)
ES (1) ES2671639T3 (cg-RX-API-DMAC7.html)
IL (1) IL238462A0 (cg-RX-API-DMAC7.html)
MX (1) MX359768B (cg-RX-API-DMAC7.html)
NZ (1) NZ708511A (cg-RX-API-DMAC7.html)
PL (1) PL2925128T3 (cg-RX-API-DMAC7.html)
TR (1) TR201807636T4 (cg-RX-API-DMAC7.html)
UA (1) UA117571C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014066870A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503741B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385243B (es) * 2014-05-19 2025-03-14 The Medicines Co Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
CN112118846B (zh) * 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂
CN114966056B (zh) * 2022-06-08 2024-07-02 四川大学华西医院 筛查急性主动脉夹层的试剂盒和系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
US8415301B2 (en) 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
CN102186351A (zh) 2008-08-01 2011-09-14 医药公司 药物组合物和用于稳定药物组合物的方法
CA3108961C (en) 2008-08-01 2024-07-02 Hospira, Inc. Pharmaceutical compositions comprising clevidipine and methods for producing low concentrations of impurities thereof
EP2498731B1 (en) * 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
WO2012051116A1 (en) * 2010-10-12 2012-04-19 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
RU2623039C2 (ru) 2011-04-01 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov archive NCT00803634(2012.6.6.) 1부.*

Also Published As

Publication number Publication date
CN110840890A (zh) 2020-02-28
NZ708511A (en) 2018-11-30
BR112015009291B1 (pt) 2021-03-16
CA2889584C (en) 2018-08-14
MX359768B (es) 2018-10-10
EA030354B1 (ru) 2018-07-31
KR20150104084A (ko) 2015-09-14
PL2925128T3 (pl) 2018-10-31
EP2925128A1 (en) 2015-10-07
JP2018065875A (ja) 2018-04-26
EA201590825A1 (ru) 2015-09-30
EP2925128A4 (en) 2016-06-08
IL238462A0 (en) 2015-06-30
CN104968199A (zh) 2015-10-07
ZA201503741B (en) 2022-09-28
AU2013334081A1 (en) 2015-06-11
BR112015009291A2 (pt) 2017-07-04
AU2013334081B2 (en) 2017-05-18
US10881645B2 (en) 2021-01-05
CA2889584A1 (en) 2014-05-01
JP2015535258A (ja) 2015-12-10
TR201807636T4 (tr) 2018-06-21
US20140121247A1 (en) 2014-05-01
JP6329957B2 (ja) 2018-05-23
EP2925128B1 (en) 2018-04-11
WO2014066870A1 (en) 2014-05-01
UA117571C2 (uk) 2018-08-27
MX2015005341A (es) 2016-05-24
ES2671639T3 (es) 2018-06-07

Similar Documents

Publication Publication Date Title
Clark et al. Causes and treatment of oedema in patients with heart failure
Jain et al. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization
US20110166220A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
EP3607962B1 (en) Angiotensin ii alone or in combination for the treatment of hypotension
US20190008815A1 (en) Sprayable aqueous composition comprising glyceryl trinitrate
AU2013334081B2 (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
MXPA06010397A (es) Perhexilina para el tratamiento de la insuficiencia cardiaca cronica.
US11911384B2 (en) Vasodilators for treatment of heart failure
HK40020897A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
US20080014187A1 (en) Compositions and Methods for Treating Hypertension and Inflammation
Tamargo et al. Class III Antiarrhythmic
WO2025128432A1 (en) Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia
Khatib Diuretics in heart failure part 2: considerations in practice
EP2387996A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
Kumar et al. Pharmacological strategies for the treatment of congestive heart failure
Sharp et al. Nesiritide for treatment of heart failure due to right ventricular dysfunction
JP2007008845A (ja) 慢性心不全治療および/または予防薬

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

T12-X000 Administrative time limit extension not granted

St.27 status event code: U-3-3-T10-T12-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5